Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06747845 · ClinicalTrials.gov registry record · Phase 2
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
A Phase 2 study of Pancreatic Adenocarcinoma Metastatic, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 2
- Study locations
NCT06747845 is a Phase 2 study of Pancreatic Adenocarcinoma Metastatic that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 68 participants, above the 45-participant average among 5 other Pancreatic Adenocarcinoma Metastatic trials with a reported enrollment target (51% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06747845, a Phase 2 study of Pancreatic Adenocarcinoma Metastatic, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer. This study will involve two different treatment arms. In Arm A, patients will receive niraparib plus ipilimumab. In Arm B, patients will receive standard chemotherapy. The main questions the study aims to answer are: * Does niraparib plus ipilimumab slow down tumor growth in patients with pancreatic cancer? * What medical problems do participants have when taking niraparib plus ipilimumab? Participants will: * Undergo screening procedures to evaluate their cancer, overall health, and suitability for the study * After passing screening, will be randomized to Arm A or B and be scheduled to receive niraparib plus ipilimumab (Arm A) or chemotherapy (Arm B) * Receive niraparib plus ipilimumab every 3 weeks (Arm A) * Receive chemotherapy every 2 weeks (Arm B) * Visit the clinic for regular checkups and tests
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG FOLFIRI
- DRUG Niraparib
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-05-07 |
| Est. Completion | 2029-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06747845
The ClinicalTrials.gov registry entry for NCT06747845 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 5 other Pancreatic Adenocarcinoma Metastatic trials with a reported enrollment target (51% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Adenocarcinoma Metastatic appearing as the primary indexed condition, and to 3 interventions - of which Ipilimumab is the first listed.
NCT06747845 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06747845 about?
NCT06747845 is a clinical study titled "Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy". The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer. This study will involve two different treatment arms. In Arm A, patients will receive niraparib plu...
What is the current status of trial NCT06747845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2025-05-07. Estimated completion is 2029-01-30.
What conditions does trial NCT06747845 study?
This clinical trial studies the following conditions: Pancreatic Adenocarcinoma Metastatic.
What interventions are being tested in trial NCT06747845?
The interventions under investigation include: Ipilimumab (DRUG), FOLFIRI (DRUG), Niraparib (DRUG).
Who is sponsoring clinical trial NCT06747845?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06747845 being conducted?
This trial has 2 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Adenocarcinoma Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
The Seven Trial: Exploiting the Unfolded Protein Response
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.